Laboratory Corporation of America Holdings (LH)

153.96
2.67 1.76
NYSE
Prev Close 151.29
Open 151.13
Day Low/High 150.89 / 155.13
52 Wk Low/High 119.38 / 190.35
Volume 790.63K
Exchange NYSE
Shares Outstanding 98.68B
Market Cap 14.23B
Div & Yield N.A. (N.A)

Latest News

LabCorp To Announce First Quarter Financial Results On April 30, 2019

LabCorp To Announce First Quarter Financial Results On April 30, 2019

LabCorp® (NYSE: LH) will release its first quarter of 2019 financial results before the market opens on Tuesday, April 30, 2019, followed by a conference call and webcast beginning at 9:00 a.

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Earns 100 Percent On Human Rights Campaign Foundation's 17th Annual Scorecard On LGBTQ Workplace Equality

LabCorp Earns 100 Percent On Human Rights Campaign Foundation's 17th Annual Scorecard On LGBTQ Workplace Equality

LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it received a perfect score of 100 on the 2019 Corporate Equality Index (CEI), the nation's premier benchmarking survey and...

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 To Accrue Contingent Interest

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 To Accrue Contingent Interest

LabCorp® (NYSE: LH) announced today that for the period of March 11, 2019 to Sept.

LabCorp Is Scheduled To Present At The 2019 Barclays Global Healthcare Conference

LabCorp Is Scheduled To Present At The 2019 Barclays Global Healthcare Conference

LabCorp® (NYSE: LH) today announced it will participate at the 2019 Barclays Global Healthcare Conference.

LabCorp Strengthens Leadership Position In Precision Medicine With Expansion Of Therapeutic Drug Monitoring Portfolio

LabCorp Strengthens Leadership Position In Precision Medicine With Expansion Of Therapeutic Drug Monitoring Portfolio

LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced a new assay in its therapeutic drug monitoring (TDM) DoseASSURE® portfolio.

LabCorp Announces 2018 Fourth Quarter And Full Year Results And Provides 2019 Guidance

LabCorp Announces 2018 Fourth Quarter And Full Year Results And Provides 2019 Guidance

LabCorp ® (or the Company) (NYSE: LH) today announced results for the fourth quarter and year ended Dec.

LabCorp Named To FORTUNE Magazine's 2019 List Of 'World's Most Admired Companies,' Making The Annual List For The Second Consecutive Year

LabCorp Named To FORTUNE Magazine's 2019 List Of 'World's Most Admired Companies,' Making The Annual List For The Second Consecutive Year

LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to  FORTUNE magazine's 2019 List of World's Most Admired Companies, making the annual list for the second consecutive year.

2 Well-Known Stocks You Should Consider Shorting This Week

2 Well-Known Stocks You Should Consider Shorting This Week

These 'Bearish Bets' are showing both technical and quantitative deterioration.

A Weight Loss Giant, a Maker of Railcars and Other Stocks That Look Good Short

TVTY, DTV, LH, GBX and WTW all recently were downgraded by TheStreet's Quant Ratings.

LabCorp To Announce Fourth Quarter And Full Year 2018 Financial Results On February 7, 2019

LabCorp To Announce Fourth Quarter And Full Year 2018 Financial Results On February 7, 2019

LabCorp® (NYSE: LH) will release its fourth quarter and full year 2018 financial results before the market opens on Thursday, Feb.

Http://www.tachc.org

Http://www.tachc.org

LabCorp® (NYSE: LH) a leading global life sciences company, and the Texas Association of Community Health Centers, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMPH, SNA, ZYME Downgrades: LH, SIMO Initiations: LXFR Read on to get TheStreet Quant Ratings' detailed report:

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

Http://www.genfit.com

Http://www.genfit.com

LabCorp® (NYSE: LH), a leading global life sciences company, and GENFIT (Euronext: GNFT), a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, have announced the signing of a...

LabCorp Is Scheduled To Present At The 37th Annual J.P. Morgan Healthcare Conference

LabCorp Is Scheduled To Present At The 37th Annual J.P. Morgan Healthcare Conference

LabCorp® (NYSE: LH) today announced it will participate at the 37th Annual J.P.

Covance Xcellerate® Wins Best Technological Development In Clinical Trials (Clinical Sponsor-Focused) At 14th Annual Scrip Awards

Covance Xcellerate® Wins Best Technological Development In Clinical Trials (Clinical Sponsor-Focused) At 14th Annual Scrip Awards

LabCorp® (NYSE: LH), a leading global life sciences company, today announced that its Covance Drug Development (Covance) business was awarded Best Technological Development in Clinical Trials (Clinical Sponsor-Focused) at the 14th Annual Scrip Awards for...

L-R, Andrew Fleming, Vice President, Head Of Business Development, Asia Pacific, Covance; Chee Hwee Lim, Vice President, Head Of Clinical Trial Operations, Asia Pacific, Covance. (Photo: Business Wire)

L-R, Andrew Fleming, Vice President, Head Of Business Development, Asia Pacific, Covance; Chee Hwee Lim, Vice President, Head Of Clinical Trial Operations, Asia Pacific, Covance. (Photo: Business Wire)

LabCorp® (NYSE: LH), a leading global life sciences company, today announced that its Covance Drug Development business (Covance) has been awarded the 2018 Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award.

Laboratory Corp. Slides on Lowered Guidance

Laboratory Corp. Slides on Lowered Guidance

Laboratory Corp. of America slides after the life sciences company lowers its 2018 guidance due to lower-than-expected volume growth in LabCorp Diagnostics.

LabCorp Updates Full-Year 2018 Guidance

LabCorp Updates Full-Year 2018 Guidance

LabCorp® (or the Company) (NYSE: LH) today updated its full-year 2018 guidance based on current expectations.

Laboratory Corporation Of America Holdings Becomes #201 Most Shorted S&P 500 Component, Replacing Varian Medical Systems

Laboratory Corporation Of America Holdings Becomes #201 Most Shorted S&P 500 Component, Replacing Varian Medical Systems

The most recent short interest data has been released for the 11/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

LabCorp At Walgreens Expands Into Southern California

LabCorp At Walgreens Expands Into Southern California

Walgreens and LabCorp® (NYSE: LH) today announced the introduction of LabCorp at Walgreens into the California Inland Empire, with nine new LabCorp patient service centers within Walgreens stores in the greater Riverside, California area.

LabCorp And Horizon Blue Cross Blue Shield Of New Jersey Renew Their Long-Standing Strategic Relationship

LabCorp And Horizon Blue Cross Blue Shield Of New Jersey Renew Their Long-Standing Strategic Relationship

Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ) and LabCorp ® (NYSE: LH) have renewed their long-standing strategic relationship to provide comprehensive clinical laboratory services for the more than 3.

Today LabCorp Announced Pixel By LabCorp, A Consumer-initiated Wellness Test Offering Which Features Sample Self-collection Anytime, Anywhere. Initial Test Offerings Are Available At Pixel.LabCorp.com, Beginning With Screens For Wellness, Heart Health, Diabetes, And Colorectal Cancer. (Photo: Business Wire)

Today LabCorp Announced Pixel By LabCorp, A Consumer-initiated Wellness Test Offering Which Features Sample Self-collection Anytime, Anywhere. Initial Test Offerings Are Available At Pixel.LabCorp.com, Beginning With Screens For Wellness, Heart Health, Diabetes, And Colorectal Cancer. (Photo: Business Wire)

LabCorp® (NYSE: LH), a leading global life sciences company, today announced the launch of Pixel by LabCorp ℠ , the latest innovation in the company's strategy to create a leading and differentiated consumer experience.

LabCorp Enables Health Records On IPhone

LabCorp Enables Health Records On IPhone

LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced it now supports Health Records on iPhone®.

LabCorp Announces 2018 Third Quarter Results And Updates 2018 Guidance

LabCorp Announces 2018 Third Quarter Results And Updates 2018 Guidance

LabCorp ® (or the Company) (NYSE: LH) today announced results for the third quarter ended September 30, 2018, and updated its 2018 guidance.

Http://www.BaptistHealth.com

Http://www.BaptistHealth.com

LabCorp® (NYSE: LH) and Baptist Health have entered into a multi-year, comprehensive laboratory collaboration.

Covance And Definiens Collaborate To Integrate Digital Pathology Into Precision Medicine Design And Development

Covance And Definiens Collaborate To Integrate Digital Pathology Into Precision Medicine Design And Development

LabCorp® (NYSE: LH), a leading global life sciences company, and Definiens®, a pioneer in artificial intelligence (AI) based image analysis, announced a strategic collaboration to improve global development of precision medicine.

TheStreet Quant Rating: C+ (Hold)